103 related articles for article (PubMed ID: 31923861)
1. Molecular design, synthesis, and biological evaluation of bisamide derivatives as cyclophilin A inhibitors for HCV treatment.
Han J; Lee HW; Jin Y; Khadka DB; Yang S; Li X; Kim M; Cho WJ
Eur J Med Chem; 2020 Feb; 188():112031. PubMed ID: 31923861
[TBL] [Abstract][Full Text] [Related]
2. SAR study of bisamides as cyclophilin a inhibitors for the development of host-targeting therapy for hepatitis C virus infection.
Li X; Han J; Lee HW; Yoon YS; Jin Y; Khadka DB; Yang S; Kim M; Cho WJ
Bioorg Med Chem; 2020 Oct; 28(19):115679. PubMed ID: 32912430
[TBL] [Abstract][Full Text] [Related]
3. Structure-Based Discovery of Novel Cyclophilin A Inhibitors for the Treatment of Hepatitis C Virus Infections.
Yang S; K R J; Lim S; Choi TG; Kim JH; Akter S; Jang M; Ahn HJ; Kim HY; Windisch MP; Khadka DB; Zhao C; Jin Y; Kang I; Ha J; Oh BC; Kim M; Kim SS; Cho WJ
J Med Chem; 2015 Dec; 58(24):9546-61. PubMed ID: 26613291
[TBL] [Abstract][Full Text] [Related]
4. Discovery of Novel Small Molecule Anti-HCV Agents via the CypA Inhibitory Mechanism Using O-Acylation-Directed Lead Optimization.
Yan W; Qing J; Mei H; Mao F; Huang J; Zhu J; Jiang H; Liu L; Zhang L; Li J
Molecules; 2015 Jun; 20(6):10342-59. PubMed ID: 26053489
[TBL] [Abstract][Full Text] [Related]
5. Molecular design, synthesis and biological evaluation of cage compound-based inhibitors of hepatitis C virus p7 ion channels.
Shiryaev VA; Radchenko EV; Palyulin VA; Zefirov NS; Bormotov NI; Serova OA; Shishkina LN; Baimuratov MR; Bormasheva KM; Gruzd YA; Ivleva EA; Leonova MV; Lukashenko AV; Osipov DV; Osyanin VA; Reznikov AN; Shadrikova VA; Sibiryakova AE; Tkachenko IM; Klimochkin YN
Eur J Med Chem; 2018 Oct; 158():214-235. PubMed ID: 30218908
[TBL] [Abstract][Full Text] [Related]
6. HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors.
Chatterji U; Lim P; Bobardt MD; Wieland S; Cordek DG; Vuagniaux G; Chisari F; Cameron CE; Targett-Adams P; Parkinson T; Gallay PA
J Hepatol; 2010 Jul; 53(1):50-6. PubMed ID: 20451281
[TBL] [Abstract][Full Text] [Related]
7. Identification of novel small molecule inhibitors against the NS3/4A protease of hepatitis C virus genotype 4a.
El-Sayed SM; Ali MAM; El-Gendy BEM; Dandash SS; Issac Y; Saad R; Azab MM; Mohamed MR
Curr Pharm Des; 2018; 24(37):4484-4491. PubMed ID: 30501598
[TBL] [Abstract][Full Text] [Related]
8. The use of AlphaLISA technology to detect interaction between hepatitis C virus-encoded NS5A and cyclophilin A.
Waller H; Chatterji U; Gallay P; Parkinson T; Targett-Adams P
J Virol Methods; 2010 May; 165(2):202-10. PubMed ID: 20132841
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the Anti-Hepatitis C Virus Activity of New Nonpeptidic Small-Molecule Cyclophilin Inhibitors with the Potential for Broad Anti-Flaviviridae Activity.
Nevers Q; Ruiz I; Ahnou N; Donati F; Brillet R; Softic L; Chazal M; Jouvenet N; Fourati S; Baudesson C; Bruscella P; Gelin M; Guichou JF; Pawlotsky JM; Ahmed-Belkacem A
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760125
[TBL] [Abstract][Full Text] [Related]
10. Anti-hepatitis-C virus activity and QSAR study of certain thiazolidinone and thiazolotriazine derivatives as potential NS5B polymerase inhibitors.
Hassan GS; Georgey HH; Mohammed EZ; Omar FA
Eur J Med Chem; 2019 Dec; 184():111747. PubMed ID: 31604164
[TBL] [Abstract][Full Text] [Related]
11. A comparative study of the efficiency of HCV NS3/4A protease drugs against different HCV genotypes using in silico approaches.
Ezat AA; Elshemey WM
Life Sci; 2019 Jan; 217():176-184. PubMed ID: 30528183
[TBL] [Abstract][Full Text] [Related]
12. Cyclophilin inhibitors reduce phosphorylation of RNA-dependent protein kinase to restore expression of IFN-stimulated genes in HCV-infected cells.
Daito T; Watashi K; Sluder A; Ohashi H; Nakajima S; Borroto-Esoda K; Fujita T; Wakita T
Gastroenterology; 2014 Aug; 147(2):463-72. PubMed ID: 24786893
[TBL] [Abstract][Full Text] [Related]
13. Exploring small molecules with pan-genotypic inhibitory activities against hepatitis C virus NS3/4A serine protease.
Ren J; Ojeda I; Patel M; Johnson ME; Lee H
Bioorg Med Chem Lett; 2019 Aug; 29(16):2349-2353. PubMed ID: 31201062
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationships of fluorene compounds inhibiting HCV variants.
Kim HS; You Y; Mun J; Gadhe CG; Moon H; Lee JS; Pae AN; Kohara M; Keum G; Kim BM; Jang SK
Antiviral Res; 2020 Feb; 174():104678. PubMed ID: 31862501
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and structure-activity relationship study of new biaryl amide derivatives and their inhibitory effects against hepatitis C virus.
Liu Y; Li J; Gu Y; Ma L; Cen S; Peng Z; Hu L
Eur J Med Chem; 2022 Jan; 228():114033. PubMed ID: 34883293
[TBL] [Abstract][Full Text] [Related]
16. Molecular design and synthesis of HCV inhibitors based on thiazolone scaffold.
Al-Ansary GH; Ismail MA; Abou El Ella DA; Eid S; Abouzid KA
Eur J Med Chem; 2013 Oct; 68():19-32. PubMed ID: 23933047
[TBL] [Abstract][Full Text] [Related]
17. Current race in the development of DAAs (direct-acting antivirals) against HCV.
De Clercq E
Biochem Pharmacol; 2014 Jun; 89(4):441-52. PubMed ID: 24735613
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and anti-HCV activity evaluation of anilinoquinoline derivatives.
Peng HK; Lin CK; Yang SY; Tseng CK; Tzeng CC; Lee JC; Yang SC
Bioorg Med Chem Lett; 2012 Jan; 22(2):1107-10. PubMed ID: 22204909
[TBL] [Abstract][Full Text] [Related]
19. Discovery of ASP5286: A novel non-immunosuppressive cyclophilin inhibitor for the treatment of HCV.
Makino T; Yoshimura S; Neya M; Yamanaka T; Sawada M; Tsujii E; Barrett D
Bioorg Med Chem Lett; 2020 Aug; 30(16):127308. PubMed ID: 32631528
[TBL] [Abstract][Full Text] [Related]
20. [RESISTANCE OF HCV TO NEW DIRECT ACTING ANTIVIRALS].
Gozlan Y; Mendelson E; Ben-Ari Z; Mor O
Harefuah; 2015 Nov; 154(11):684-7, 743. PubMed ID: 26821497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
